Kathy A. Barrett

650-***-****

ac83tp@r.postjobfree.com

PROFESSIONAL SUMMARY

Experienced drug discovery scientist with expertise in small and large molecule screening, in vitro assay development, cell tissue preparation and IHC, basic molecular biology techniques, primary cell culture, and T-cell isolation and activation.

Proficiency with FRET, fluorescence, and luminescence screening assay techniques; cell culture and sterile technique; ex-vivo assay development; ELISA; MSD; cell culture and cellular assay development (proliferation, viability assays, biomarker assays); protein quantification using Western blotting; kinase assay development; enzyme kinetics/binding profile studies; in-situ hybridization; immunohistochemistry; high content imaging.

Strong analytical skills with the ability to independently design and implement research projects.

Advanced computer skills, including graphing programs and chemistry databases: ISIS Base, Activity Base; Microsoft Excel, PowerPoint, Word; Prism, SigmaPlot; StatView; Genedata, Assay Explorer; Seurat.

RESEARCH EXPERIENCE

Genentech, South San Francisco, CA, September 2007-present

Senior Scientific Researcher, Biochemical and Cellular Pharmacology

Assay development for large and small molecule projects in numerous therapeutic areas including Immunology, Oncology, and Immuno-oncology.

Assays for T-cell activation by bivalent and T-dependent bispecific (TDB) antibodies and T-cell-mediated killing of tumor cells by TDB’s for immune-oncology programs.

Development of a high content imaging assay to measure the nuclear translocation of p52 in B cells isolated from stimulated human whole blood.

Isolation of PBMC’s from human whole blood, and isolation of leukocyte subsets (CD4 T cells (naïve and memory); B cells and monocytes) from PBMC’s.

Development of cellular assays using cell lines, peripheral blood mononuclear cells (PBMC) and whole blood for the evaluation of small molecular inhibitors of several Jak kinases.

SAR (structural activity relationship) screening of candidate small molecules performed in a highly efficient and timely manner. Communication of results to chemists and other team members.

Analysis of biomarker (mostly phosphoproteins) expression in in vivo tissue samples, including liver and spleen lysates. Development of the assay, which is critical for establishing the primary in vivo model for the Jak2 program.

Regular presentation of my data at project team and departmental meetings.

Biochemical assay development for NIK kinase, using several different platforms—including KinaseGlo, Alphascreen.

Attendance at meetings of professional societies (American Society of Hematology) and courses relevant to my field (American Association of Immunologists, Introductory Immunology course, AAI Advanced Immunology Course).

Neurocrine Biosciences, San Diego, CA, February 2006-August 2007

Associate Scientist, Pharmacology

Development of a broad range of assays to assess small molecule performance, including cAMP accumulation, radioactive binding, Ca2+ flux and drug transport into cells.

SAR screening utilizing many automation platforms, including Multimek, Biomek 2000, Minitrak, FLIPR Tetra.

Targegen, Inc., San Diego, CA- October 2002-February 2006

Senior Research Associate, In Vitro Pharmacology

Development of biochemical and cell-based assays, including binding and mechanism of binding studies for kinase inhibitors.

Supervision of junior research associate.

Rated among the top five performers in the company during final performance review.

Co-inventor on two patents for small molecules developed for Oncology and Ocular programs at Targegen.

LION Bioscience, San Diego, CA, December 2001-October 2002

Senior Research Associate, Biology Department

Information technology driven screening of compounds targeting the nuclear hormone receptors FXR and LXR. Responsibilities included primary and secondary screening (96- and 384-well formats) of small molecule and combinatorial chemistry libraries, extensive data analysis, and troubleshooting FRET assays.

EDUCATION

University of Rochester School of Medicine & Dentistry, Rochester, New York

Department of Neurology/Neurobiology & Anatomy Graduate Program

Lehigh University, Bethlehem, Pennsylvania

B.S, Chemical Engineering

PUBLICATIONS

1.Dengler HS, Wu X, Peng I, Rinderknecht CH, Kwon Y, Suto E, Kohli PB, Liimatta M, Barrett K, Lloyd J, Cain G, Briggs M, Addo S, Salmon G, Ubhayakar S, Deshmukh G, Shahidi-Latham SK, Quiason-Huynh CM, Jackman J, Liu J, Ray NC, Goodacre SC,Johnson A, McKenzie BS, Lee WP, Zak M, Kenny JR, Ghilardi N. Lung-restricted inhibition of Janus kinase 1 is effective in rodent models of asthma. Sci Transl Med. 2018 Nov 21;10(468). pii: eaao2151. doi: 10.1126/scitranslmed.aao2151. PubMed PMID: 30463918.

2. Brightbill HD, Suto E, Blaquiere N, Ramamoorthi N, Sujatha-Bhaskar S, Gogol EB, Castanedo GM, Jackson BT, Kwon YC, Haller S, Lesch J, Bents K, Everett C,Kohli PB, Linge S, Christian L, Barrett K, Jaochico A, Berezhkovskiy LM, Fan PW, Modrusan Z, Veliz K, Townsend MJ, DeVoss J, Johnson AR, Godemann R, Lee WP,Austin CD, McKenzie BS, Hackney JA, Crawford JJ, Staben ST, Alaoui Ismaili MH, Wu LC, Ghilardi N. NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus. Nat Commun. 2018 Jan 12;9(1):179. doi: 10.1038/s41467-017-02672-0. PubMed PMID: 29330524; PubMed Central PMCID: PMC5766581.

3. Liang J, Van Abbema A, Balazs M, Barrett K, Berezhkovsky L, Blair WS, Chang C,Delarosa D, DeVoss J, Driscoll J, Eigenbrot C, Goodacre S, Ghilardi N, MacLeod C,Johnson A, Bir Kohli P, Lai Y, Lin Z, Mantik P, Menghrajani K, Nguyen H, Peng I, Sambrone A, Shia S, Smith J, Sohn S, Tsui V, Ultsch M, Williams K, Wu LC, Yang W,Zhang B, Magnuson S. Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model. Bioorg Med Chem Lett. 2017 Sep 15;27(18):4370-4376. doi: 10.1016/j.bmcl.2017.08.022. Epub 2017 Aug 12. PubMed PMID: 28830649.

4. Sun Y, Peng I, Webster JD, Suto E, Lesch J, Wu X, Senger K, Francis G, Barrett K, Collier JL, Burch JD, Zhou M, Chen Y, Chan C, Eastham-Anderson J, Ngu H, Li O,Staton T, Havnar C, Jaochico A, Jackman J, Jeet S, Riol-Blanco L, Wu LC, Choy DF,Arron JR, McKenzie BS, Ghilardi N, Ismaili MH, Pei Z, DeVoss J, Austin CD, Lee WP, Zarrin AA. Inhibition of the kinase ITK in a mouse model of asthma reduces cell death and fails to inhibit the inflammatory response. Sci Signal. 2015 Dec 1;8(405):ra122. doi: 10.1126/scisignal.aab0949. PubMed PMID: 26628680.

5. Labade S, Barrett K, Blair WS, Chang C, Deshmukh G, Eigenbrot C, Gibbons P,Johnson A, Kenny JR, Kohli PB, Liimatta M, Lupardus PJ, Shia S, Steffek M,Ubhayakar S, van Abbema A, Zak M. Design and evaluation of novel 8-oxo-pyridopyrimidine Jak1/2 inhibitors. Bioorg Med Chem Lett. 2013 Nov 1;23(21):5923-30. doi: 10.1016/j.bmcl.2013.08.082. Epub 2013 Aug 27. PubMed PMID: 24042009.

6. Sohn SJ, Barrett K, Van Abbema A, Chang C, Kohli PB, Kanda H, Smith J, Lai Y, Zhou A, Zhang B, Yang W, Williams K, Macleod C, Hurley CA, Kulagowski JJ,Lewin-Koh N, Dengler HS, Johnson AR, Ghilardi N, Zak M, Liang J, Blair WS,Magnuson S, Wu LC. A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors. J Immunol. 2013 Sep 1;191(5):2205-16. doi: 0.4049/jimmunol.1202859. Epub 2013 Jul 26. PubMed PMID: 23894201; PubMed Central PMCID: PMC3748334.

7. Liang J, Tsui V, Van Abbema A, Bao L, Barrett K, Beresini M, Berezhkovskiy L, Blair WS, Chang C, Driscoll J, Eigenbrot C, Ghilardi N, Gibbons P, Halladay J, Johnson A, Kohli PB, Lai Y, Liimatta M, Mantik P, Menghrajani K, Murray J, Sambrone A, Xiao Y, Shia S, Shin Y, Smith J, Sohn S, Stanley M, Ultsch M, Zhang B, Wu LC, Magnuson S. Lead identification of novel and selective TYK2 inhibitors. Eur J Med Chem. 2013 Sep;67:175-87. doi: 10.1016/j.ejmech.2013.03.070. Epub 2013 May 14. PubMed PMID: 23867602.

8. Liang J, van Abbema A, Balazs M, Barrett K, Berezhkovsky L, Blair W, Chang C, Delarosa D, DeVoss J, Driscoll J, Eigenbrot C, Ghilardi N, Gibbons P, Halladay J, Johnson A, Kohli PB, Lai Y, Liu Y, Lyssikatos J, Mantik P, Menghrajani K, Murray J, Peng I, Sambrone A, Shia S, Shin Y, Smith J, Sohn S, Tsui V, Ultsch M, Wu LC, Xiao Y, Yang W, Young J, Zhang B, Zhu BY, Magnuson S. Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors. J Med Chem. 2013 Jun 13;56(11):4521-36. doi: 10.1021/jm400266t. Epub 2013 May 29. PubMed PMID: 23668484.

9. Zak M, Hurley CA, Ward SI, Bergeron P, Barrett K, Balazs M, Blair WS, Bull R, Chakravarty P, Chang C, Crackett P, Deshmukh G, DeVoss J, Dragovich PS, Eigenbrot C, Ellwood C, Gaines S, Ghilardi N, Gibbons P, Gradl S, Gribling P, Hamman C, Harstad E, Hewitt P, Johnson A, Johnson T, Kenny JR, Koehler MF, Bir Kohli P,Labadie S, Lee WP, Liao J, Liimatta M, Mendonca R, Narukulla R, Pulk R, Reeve A, Savage S, Shia S, Steffek M, Ubhayakar S, van Abbema A, Aliagas I, Avitabile-Woo B, Xiao Y, Yang J, Kulagowski JJ. Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2. J Med Chem. 2013 Jun 13;56(11):4764-85. doi: 10.1021/jm4004895. Epub 2013 May 31. PubMed PMID: 23659214.

10. Labadie S, Dragovich PS, Barrett K, Blair WS, Bergeron P, Chang C, Deshmukh G, Eigenbrot C, Ghilardi N, Gibbons P, Hurley CA, Johnson A, Kenny JR, Kohli PB, Kulagowski JJ, Liimatta M, Lupardus PJ, Mendonca R, Murray JM, Pulk R, Shia S, Steffek M, Ubhayakar S, Ultsch M, van Abbema A, Ward S, Zak M. Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2. Bioorg Med Chem Lett. 2012 Dec 15;22(24):7627-33. doi: 10.1016/j.bmcl.2012.10.008. Epub 2012 Oct 11. PubMed PMID: 23107482.

11. Hanan EJ, van Abbema A, Barrett K, Blair WS, Blaney J, Chang C, Eigenbrot C, Flynn S, Gibbons P, Hurley CA, Kenny JR, Kulagowski J, Lee L, Magnuson SR, Morris C, Murray J, Pastor RM, Rawson T, Siu M, Ultsch M, Zhou A, Sampath D, Lyssikatos JP. Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors. J Med Chem. 2012 Nov 26;55(22):10090-107. doi: 10.1021/jm3012239. Epub 2012 Oct 24. PubMed PMID: 23061660.

12. Zak M, Mendonca R, Balazs M, Barrett K, Bergeron P, Blair WS, Chang C, Deshmukh G, Devoss J, Dragovich PS, Eigenbrot C, Ghilardi N, Gibbons P, Gradl S, Hamman C, Hanan EJ, Harstad E, Hewitt PR, Hurley CA, Jin T, Johnson A, Johnson T,Kenny JR, Koehler MF, Bir Kohli P, Kulagowski JJ, Labadie S, Liao J, Liimatta M, Lin Z, Lupardus PJ, Maxey RJ, Murray JM, Pulk R, Rodriguez M, Savage S, Shia S, Steffek M, Ubhayakar S, Ultsch M, van Abbema A, Ward SI, Xiao L, Xiao Y. Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent andorally bioavailable JAK1 inhibitors with selectivity over JAK2. J Med Chem. 2012 Jul 2;55(13):6176-93. doi: 10.1021/jm300628c. Epub 2012 Jun 28. PubMed PMID: 22698084.

13. Noronha G, Barrett K, Boccia A, Brodhag T, Cao J, Chow CP, Dneprovskaia E, Doukas J, Fine R, Gong X, Gritzen C, Gu H, Hanna E, Hood JD, Hu S, Kang X, Key J, Klebansky B, Kousba A, Li G, Lohse D, Mak CC, McPherson A, Palanki MS, Pathak VP, Renick J, Shi F, Soll R, Splittgerber U, Stoughton S, Tang S, Yee S, Zeng B, Zhao N, Zhu H. Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays. Bioorg Med Chem Lett. 2007 Feb 1;17(3):602-8. Epub 2006 Nov 7. PubMed PMID:17113292.

14. Noronha G, Barrett K, Cao J, Dneprovskaia E, Fine R, Gong X, Gritzen C, Hood J, Kang X, Klebansky B, Li G, Liao W, Lohse D, Mak CC, McPherson A, Palanki MS,Pathak VP, Renick J, Soll R, Splittgerber U, Wrasidlo W, Zeng B, Zhao N, Zhou Y. Discovery and preliminary structure-activity relationship studies of novel benzotriazine based compounds as Src inhibitors. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5546-50. Epub 2006 Aug 22. PubMed PMID: 16931012.

15. Winokur ST, Barrett K, Martin JH, Forrester JR, Simon M, Tawil R, Chung SA, Masny PS, Figlewicz DA. Facioscapulohumeral muscular dystrophy (FSHD) myoblasts demonstrate increased susceptibility to oxidative stress. Neuromuscul Disord. 2003 May;13(4):322-33. PubMed PMID: 12868502.

16. Kellogg CK, Barrett KA. Reduced progesterone metabolites are not critical for plus-maze performance of lactating female rats. Pharmacol Biochem Behav. 1999 Jul;63(3):441-8. PubMed PMID:

Contact this candidate